Verification of foetal Down syndrome biomarker proteins in maternal plasma and applications in prenatal screening for Down syndrome
Abstract Background Down Syndrome (DS) has a very high morbidity, according to statistics, the incidence rate of DS is as high as 1:700 among the new born babies. At present, there are still no effective prevention or treatment methods for the disease. We used a Western Blot technique to validate di...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-11-01
|
| Series: | Translational Medicine Communications |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s41231-018-0028-x |
| _version_ | 1819063577084952576 |
|---|---|
| author | Weiguo Sui Qing Gan Wei Wei Gong Xiaolian Wei Minglin Ou Donge Tang Huanyun Jing Hua Lin Yue Zhang Yong Dai |
| author_facet | Weiguo Sui Qing Gan Wei Wei Gong Xiaolian Wei Minglin Ou Donge Tang Huanyun Jing Hua Lin Yue Zhang Yong Dai |
| author_sort | Weiguo Sui |
| collection | DOAJ |
| description | Abstract Background Down Syndrome (DS) has a very high morbidity, according to statistics, the incidence rate of DS is as high as 1:700 among the new born babies. At present, there are still no effective prevention or treatment methods for the disease. We used a Western Blot technique to validate differentially expressed proteins between DS foetal umbilical cord blood plasma and healthy foetal peripheral blood plasma from pregnant women to identify new prenatal diagnostic biomarkers for down syndrome (DS) and establish a new non-invasive prenatal diagnosis method. Methods We collected maternal peripheral blood (8 with foetal DS and 8 from normal foetuses) from April 2013 to January 2014, and separated the plasma. We combined the clinical characteristics and clinical differentially expressed proteins between DS foetal umbilical cord blood plasma and healthy foetal umbilical cord blood plasma to identify specific protein marker candidates and prepared monoclonal antibodies, which were then used for Western Blot technique to analyse the candidate markers. Results In the DS foetal maternal plasma, serum amyloid P-component, Apolipoprotein E, Nucleosome assembly protein 1-like 1, Complement factor B,ERO1-like protein alpha, 2-oxoglutarate dehydrogenase-like, and Thymosin beta 10 were up-regulated proteins compared to the healthy control group, and the DS group showed higher expression, which agreed with the results from the DS foetal umbilical cord blood plasma. Conclusion The up-regulated amyloid P-component, Apolipoprotein E, Nucleosome assembly protein 1-like 1, Complement factor B, ERO1-like protein alpha, 2-oxoglutarate dehydrogenase-like, Thymosin beta 10 all are up-regulation, all of them have potential to be prenatal diagnosis biomarkers for DS, and these biomarkers can further reveal the pathogenesis of DS. |
| first_indexed | 2024-12-21T15:16:53Z |
| format | Article |
| id | doaj.art-b829d3d25cd943d2bc5caff092b24097 |
| institution | Directory Open Access Journal |
| issn | 2396-832X |
| language | English |
| last_indexed | 2024-12-21T15:16:53Z |
| publishDate | 2018-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Translational Medicine Communications |
| spelling | doaj.art-b829d3d25cd943d2bc5caff092b240972022-12-21T18:59:08ZengBMCTranslational Medicine Communications2396-832X2018-11-01311810.1186/s41231-018-0028-xVerification of foetal Down syndrome biomarker proteins in maternal plasma and applications in prenatal screening for Down syndromeWeiguo Sui0Qing Gan1Wei Wei Gong2Xiaolian Wei3Minglin Ou4Donge Tang5Huanyun Jing6Hua Lin7Yue Zhang8Yong Dai9Nephrology Department of Guilin No. 181 Hospital, Guangxi Key laboratory of Metabolic Diseases Research, Guilin Key laboratory of Kidney Diseases ResearchNephrology Department of Guilin No. 181 Hospital, Guangxi Key laboratory of Metabolic Diseases Research, Guilin Key laboratory of Kidney Diseases ResearchNephrology Department of Guilin No. 181 Hospital, Guangxi Key laboratory of Metabolic Diseases Research, Guilin Key laboratory of Kidney Diseases ResearchCollege of Life Science, Guangxi Normal UniversityNephrology Department of Guilin No. 181 Hospital, Guangxi Key laboratory of Metabolic Diseases Research, Guilin Key laboratory of Kidney Diseases ResearchClinical Medical Research Center, the Second Clinical Medical College of Jinan University (Shenzhen People’s Hospital)Nephrology Department of Guilin No. 181 Hospital, Guangxi Key laboratory of Metabolic Diseases Research, Guilin Key laboratory of Kidney Diseases ResearchNephrology Department of Guilin No. 181 Hospital, Guangxi Key laboratory of Metabolic Diseases Research, Guilin Key laboratory of Kidney Diseases ResearchNephrology Department of Guilin No. 181 Hospital, Guangxi Key laboratory of Metabolic Diseases Research, Guilin Key laboratory of Kidney Diseases ResearchNephrology Department of Guilin No. 181 Hospital, Guangxi Key laboratory of Metabolic Diseases Research, Guilin Key laboratory of Kidney Diseases ResearchAbstract Background Down Syndrome (DS) has a very high morbidity, according to statistics, the incidence rate of DS is as high as 1:700 among the new born babies. At present, there are still no effective prevention or treatment methods for the disease. We used a Western Blot technique to validate differentially expressed proteins between DS foetal umbilical cord blood plasma and healthy foetal peripheral blood plasma from pregnant women to identify new prenatal diagnostic biomarkers for down syndrome (DS) and establish a new non-invasive prenatal diagnosis method. Methods We collected maternal peripheral blood (8 with foetal DS and 8 from normal foetuses) from April 2013 to January 2014, and separated the plasma. We combined the clinical characteristics and clinical differentially expressed proteins between DS foetal umbilical cord blood plasma and healthy foetal umbilical cord blood plasma to identify specific protein marker candidates and prepared monoclonal antibodies, which were then used for Western Blot technique to analyse the candidate markers. Results In the DS foetal maternal plasma, serum amyloid P-component, Apolipoprotein E, Nucleosome assembly protein 1-like 1, Complement factor B,ERO1-like protein alpha, 2-oxoglutarate dehydrogenase-like, and Thymosin beta 10 were up-regulated proteins compared to the healthy control group, and the DS group showed higher expression, which agreed with the results from the DS foetal umbilical cord blood plasma. Conclusion The up-regulated amyloid P-component, Apolipoprotein E, Nucleosome assembly protein 1-like 1, Complement factor B, ERO1-like protein alpha, 2-oxoglutarate dehydrogenase-like, Thymosin beta 10 all are up-regulation, all of them have potential to be prenatal diagnosis biomarkers for DS, and these biomarkers can further reveal the pathogenesis of DS.http://link.springer.com/article/10.1186/s41231-018-0028-xBiomarkersDown’s syndromeMaternal blood plasmaPrenatal screeningWestern blot |
| spellingShingle | Weiguo Sui Qing Gan Wei Wei Gong Xiaolian Wei Minglin Ou Donge Tang Huanyun Jing Hua Lin Yue Zhang Yong Dai Verification of foetal Down syndrome biomarker proteins in maternal plasma and applications in prenatal screening for Down syndrome Translational Medicine Communications Biomarkers Down’s syndrome Maternal blood plasma Prenatal screening Western blot |
| title | Verification of foetal Down syndrome biomarker proteins in maternal plasma and applications in prenatal screening for Down syndrome |
| title_full | Verification of foetal Down syndrome biomarker proteins in maternal plasma and applications in prenatal screening for Down syndrome |
| title_fullStr | Verification of foetal Down syndrome biomarker proteins in maternal plasma and applications in prenatal screening for Down syndrome |
| title_full_unstemmed | Verification of foetal Down syndrome biomarker proteins in maternal plasma and applications in prenatal screening for Down syndrome |
| title_short | Verification of foetal Down syndrome biomarker proteins in maternal plasma and applications in prenatal screening for Down syndrome |
| title_sort | verification of foetal down syndrome biomarker proteins in maternal plasma and applications in prenatal screening for down syndrome |
| topic | Biomarkers Down’s syndrome Maternal blood plasma Prenatal screening Western blot |
| url | http://link.springer.com/article/10.1186/s41231-018-0028-x |
| work_keys_str_mv | AT weiguosui verificationoffoetaldownsyndromebiomarkerproteinsinmaternalplasmaandapplicationsinprenatalscreeningfordownsyndrome AT qinggan verificationoffoetaldownsyndromebiomarkerproteinsinmaternalplasmaandapplicationsinprenatalscreeningfordownsyndrome AT weiweigong verificationoffoetaldownsyndromebiomarkerproteinsinmaternalplasmaandapplicationsinprenatalscreeningfordownsyndrome AT xiaolianwei verificationoffoetaldownsyndromebiomarkerproteinsinmaternalplasmaandapplicationsinprenatalscreeningfordownsyndrome AT minglinou verificationoffoetaldownsyndromebiomarkerproteinsinmaternalplasmaandapplicationsinprenatalscreeningfordownsyndrome AT dongetang verificationoffoetaldownsyndromebiomarkerproteinsinmaternalplasmaandapplicationsinprenatalscreeningfordownsyndrome AT huanyunjing verificationoffoetaldownsyndromebiomarkerproteinsinmaternalplasmaandapplicationsinprenatalscreeningfordownsyndrome AT hualin verificationoffoetaldownsyndromebiomarkerproteinsinmaternalplasmaandapplicationsinprenatalscreeningfordownsyndrome AT yuezhang verificationoffoetaldownsyndromebiomarkerproteinsinmaternalplasmaandapplicationsinprenatalscreeningfordownsyndrome AT yongdai verificationoffoetaldownsyndromebiomarkerproteinsinmaternalplasmaandapplicationsinprenatalscreeningfordownsyndrome |